Ex-ICMR DG clears the air on Covaxin's phase-3 trial data and delay in WHO approval

"It was foolish to apply to US FDA for approval because even in the emergency authorisation vaccine guidelines you have to complete phase three and wait for two months for safety data"---Dr NK Ganguly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/35aJwNw
via IFTTT